Leerink Partners on Sarepta Therapeutics (SRPT): siRNA data 'a bit of a mixed bag'
Tweet Send to a Friend
Leerink Partners analyst Joseph P. Schwartz reiterated a Market Perform rating and $15.00 price target on Sarepta Therapeutics (NASDAQ: SRPT)The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
